Previously, only people with diabetes who required multiple daily insulin injections were eligible for Medicare coverage of implantable CGMs. This new policy removes that restriction, making the Eversense E3 accessible to all insulin users as well as non-insulin users with a history of problematic hypoglycemia.
The Eversense E3 is unique because it offers:
- Up to 6 months of sensor wear compared to the usual 2-week lifespan of traditional CGMs, reducing the need for frequent insertions and replacements.
- Exceptional accuracy with a demonstrated mean absolute relative difference (MARD) of 8.5%.
- A removable transmitter that allows users to take it off without wasting a sensor or waiting for a warmup period.
- Predictive on-body alerts to help prevent critical events, especially during sleep or when away from a phone.
